Chemomab Therapeutics Ltd
NASDAQ:CMMB
Chemomab Therapeutics Ltd
NASDAQ:CMMB
Price:
0.87 USD
-0.23%
Market Closed
Updated:
May 18, 2024
Chemomab Therapeutics Ltd
Cost of Revenue
|
Chemomab Therapeutics Ltd
Cost of Revenue Peer Comparison
Comparables:
CLGN
KMDA
URGN
ENTX
B
BONS
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Cost of Revenue
-$3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cost of Revenue
-$1.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cost of Revenue
-$87m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cost of Revenue
-$9.4m
|
CAGR 3-Years
-110%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cost of Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Chemomab Therapeutics Ltd's Cost of Revenue?
Cost of Revenue
-3.4m
USD
-3.4m
USD
Based on the financial report for Dec 31, 2023, Chemomab Therapeutics Ltd's Cost of Revenue amounts to -3.4m USD.
What is Chemomab Therapeutics Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-17%
-17%
Over the last year, the Cost of Revenue growth was -17%.
You don't have any saved screeners yet
